NAVIDEA BIOPHARMACEUTICALS, INC. - FORM 10-Q - EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER OF PERIODIC FINANCIAL REPORTS PURSUANT - May 10, 2011

Attached files

file filename
10-Q - QUARTERLY REPORT - NAVIDEA BIOPHARMACEUTICALS, INC.v221640_10q.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANE - NAVIDEA BIOPHARMACEUTICALS, INC.v221640_ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANE - NAVIDEA BIOPHARMACEUTICALS, INC.v221640_ex31-1.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF PERIODIC FINANCIAL REPORTS PURSUANT - NAVIDEA BIOPHARMACEUTICALS, INC.v221640_ex32-1.htm
Exhibit 32.2
 
CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, 18 U.S.C. SECTION 1350
 
The undersigned hereby certifies that he is the duly appointed and acting Chief Financial Officer of Neoprobe Corporation (the “Company”) and hereby further certifies as follows:

(1) The periodic report containing financial statements to which this certificate is an exhibit fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the periodic report to which this certificate is an exhibit fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned has executed and delivered this certificate as of the date set forth opposite his signature below.

May 10, 2011
    
/s/ Brent L. Larson
  
 
    
Brent L. Larson
  
 
    
Senior Vice President and Chief Financial Officer
  
 
 
 
 

NAVIDEA BIOPHARMACEUTICALS, INC. Reports